Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pegilodecakin · LY-3500518, AM-0010

Recombinant protein · Immune activation · developed by ELI LILLY &

Phase 1 Most advanced trial (none active)
LLY Developer

What is Pegilodecakin?

Pegilodecakin is a PEG-conjugated recombinant human IL-10 designed to activate cell-mediated immunity by stimulating CD8+ T cell differentiation and expansion. It may reduce pro-inflammatory cytokine production and lower serum cholesterol. The drug is studied in healthy adult subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY-3500518, AM-0010
Drug type
Recombinant protein
Mechanism
Immune activation
Pathways
cell-mediated immunity, CD8+ T cell differentiation and expansion, pro-inflammatory cytokine inhibition
Therapy area
Immunology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
5Z9850I25F

Conditions studied

Healthy Adult Subjects

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Pegilodecakin

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.